-
5 trends for the interbody fusion cage market
The interbody fusion cage market is expected to grow through 2025, according to a MarketReserachNest report. -
Penn Medicine researchers make stem cell discoveries: 3 key notes
Penn Engineering researchers recently examined stem cell transformation and found they could have more influence on shaping their environment and determining functionality, according to a Penn Today report. -
5 observations on spinal biologics
Here are five trends on the evolution of spinal biologics and what to expect in the future. -
Spinal fusion: Expandable vs. static cage for MIS TLIF – 5 findings
Research presented at the Society for Minimally Invasive Spine Surgery Annual Forum in 2018 compares static and expandable interbody devices for minimally invasive transforaminal lumbar interbody fusion. -
3 things to know about the future of biologics in spine surgery
Spine surgery is shifting away from traditional devices and toward biologics, a material that attracts cells to increase bone formation in spinal fusion procedures, according to Jeffrey Wang, MD, who is the University of California-Los Angeles spine service chief and director of UCLA's spine surgery fellowship. -
Spinal fusion rates – 6 things to know about ALIF
A new study published in The Spine Journal examines fusion rate for standalone anterior lumbar interbody fusions. -
New York attorney general sues stem cell clinic over unproven procedures — 8 insights
New York Attorney General Letitia James is suing New York City-based Park Avenue Stem Cell alleging the clinic performed unproven and rogue procedures on patients, the New York Times reports. -
The cost-benefit of BMP for scoliosis surgery: 5 key findings
A new study published in the Journal of Neurosurgery: Spine examines the role of BMP use during spinal deformity cases. -
Awake spinal fusion - 5 key findings
The Journal of Neurosurgery published an article outlining "awake spinal fusion" using the endoscopic transforaminal lumbar interbody fusion technique without general anesthesia. -
InVivo Therapeutics lowers net loss, realizes $11.8M cost savings in 2018: 4 key notes
InVivo Therapeutics reported raising net proceeds of $16.5 million in 2018 and implemented significant cost savings measures last year. -
Bioventus launches new bone graft substitute —- 3 things to know
Bioventus launched Osteoamp Select Fibers for use with its bone graft substitutes for spine, foot, ankle orthopedic and trauma surgeons. -
Bone morphogenetic protein use in MIS TLIF leads to 97.9% fusion rate in study — 5 things to know
Using the bone morphogenetic protein rhBMP-2 in the disc space for minimally invasive transforaminal lumbar interbody fusion led to a 97.9 percent fusion rate, according to a study in Clinical Spine Surgery. -
Global spinal biologics market to reach $2.55B by 2024 — 3 insights
The global spinal biologics market is projected to grow at a 3.6 percent compound annual growth rate to reach $2.55 billion by 2024, according to a Market Study Report. -
13 key players in the non-metal orthopedic biomaterial market
Here are 13 key players in the global non-metal orthopedic biomaterial market, according to a Markets N Research report. -
AlloSource enrolls 1st patient in cartilage defect repair study: 3 notes
AlloSource enrolled the first patient in a study of its ProChondrix CR for articular cartilage defect repair. -
FDA clears Atreon Orthopedics' regenerative rotator cuff product — 4 insights
The FDA cleared Atreon Orthopedics' Rotium Bioresorbable Wick for healing rotator cuff injuries. -
Healthcare attorney examines the future of regenerative medicine
Barbara A. Binzak Blumenfeld, PhD, is a shareholder at Buchanan Ingersoll & Rooney. She focuses her practice on the regulation of biologic research, and recently spoke with Becker’s Spine Review about where regenerative medicine is headed. -
CollPlant & Arthrex renew distribution agreement for tendinopathy treatment: 3 notes
Regenerative medicine company CollPlant renewed its exclusive distribution agreement with Arthrex for its soft tissue repair product Vergenix STR. -
IMAC Holdings taps Mike Ditka to serve as brand ambassador — 3 insights
Regenerative medicine company IMAC Holdings has a new brand ambassador in former Chicago Bears coach Mike Ditka. -
Structural allograft vs. intervertebral cages in ACDF: 3 things to know
Structural allograft may be superior to intervertebral cages in anterior cervical discectomy and fusion, according to a study in Spine.
Page 20 of 34